Memorial Healthcare International S.R.L. — Clinical Trial Site

68 Registered trials

30 Currently recruiting

Organisation

Memorial Healthcare International S.R.L.

Location

Bucharest, Romania

Identifier

ORG-100048503

Address

Soseaua Ionescu-Sisesti Gheorghe Nr 8a, 013823, Romania

Departments

040001: Medical Oncology
93150012:Medical Oncology
Departament Clinic de Gastroenterologie
Departament Clinic Oncologie Medicala
Gastroenterologie
Gastroenterology
Gstroenterology
Medical Oncology
Medical Oncology Department
Oncologie
Oncologie Medicala
Oncology
Ongologie Medicala
Secţia Oncologie Medicală

Clinical trials at this site (68)

Search interface

Phase III study of Pembrolizumab plus chemoradiation vs chemoradiation along for patients with muscle invasive bladder cancer Ended

2023-503500-87-00 Muscle Invasive Bladder Cancer 11 2020-03-17
LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended

2023-507657-15-00 Ulcerative Colitis 5 2018-09-13
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended

2023-504820-24-00 Neoadjuvant/Adjuvant treatment for participants with Re 5 2018-03-21
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo®… Ended

2023-507865-24-00 Advanced (unresectable/metastatic) melanoma 5 2025-03-28
Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504673-20-00 Ulcerative Colitis 4 2023-12-06
Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended

2023-506046-24-00 Ulcerative Colitis (UC) 4 2023-07-03
ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended

2022-500536-11-01 Moderately to severely active ulcerative colitis 5 2023-06-08
Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis Ended

2023-506004-93-00 Ulcerative Colitis (UC) 4 2022-03-01
Study of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Given with Chemotherapy, to Treat Metastatic Squamous or Non Squamous … Ended

2023-508308-40-00 Metastatic (stage IV) squamous or nonsquamous non-small 5 2021-07-30
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal … Ended

2022-501342-29-00 Esophageal Carcinoma 5 2021-07-21
Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread Ended

2022-500820-31-00 Recurrent or metastatic squamous cell carcinoma of the 4 2020-07-16
A Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherap… Ended

2022-501531-16-00 esophageal carcinoma 5 2020-01-24
Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLC Ended

2023-508449-41-00 Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) 5 2019-06-26
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC Ended

2023-509774-40-00 Stage IV lung cancer condition 5 2019-06-25
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended

2024-511553-22-00 Moderately to Severely Active Crohn's Disease 5 2018-10-05
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease Ended

2023-510426-33-00 Moderately to Severely Active Crohn's Disease 5 2018-09-27
The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the treatment of ulcerative colitis (UC) Ended

2024-514815-92-00 Ulcerative colitis 5 2015-07-16
A trial to show the similarity in effects, safety and immune response of FYB206 compared to Keytruda in people with metastatic non-squamous … Ended

2023-509766-37-00 NSCLC 5
A study to investigate the safety, tolerability, pharmacokinetics (PK), and preliminary anticancer activity of GSK4524101 alone or with nira… Ended

2024-520197-36-00 Neoplasms 7